This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).
Inclusion Criteria:
Exclusion Criteria:
lai_xiaojuan@vcarepharmatech.com
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata